Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Interaction of lapatinib with cytochrome P450 3A5.

Chan EC, New LS, Chua TB, Yap CW, Ho HK, Nelson SD.

Drug Metab Dispos. 2012 Jul;40(7):1414-22. doi: 10.1124/dmd.112.044958. Epub 2012 Apr 17.

2.

Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.

Teng WC, Oh JW, New LS, Wahlin MD, Nelson SD, Ho HK, Chan EC.

Mol Pharmacol. 2010 Oct;78(4):693-703. doi: 10.1124/mol.110.065839. Epub 2010 Jul 12.

3.

Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.

Takakusa H, Wahlin MD, Zhao C, Hanson KL, New LS, Chan EC, Nelson SD.

Drug Metab Dispos. 2011 Jun;39(6):1022-30. doi: 10.1124/dmd.110.037531. Epub 2011 Mar 1.

4.

Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.

Sugiyama M, Fujita K, Murayama N, Akiyama Y, Yamazaki H, Sasaki Y.

Drug Metab Dispos. 2011 May;39(5):757-62. doi: 10.1124/dmd.110.037853. Epub 2011 Jan 25.

5.

Metabolism-dependent inhibition of CYP3A4 by lapatinib: evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate.

Barbara JE, Kazmi F, Parkinson A, Buckley DB.

Drug Metab Dispos. 2013 May;41(5):1012-22. doi: 10.1124/dmd.113.051151. Epub 2013 Feb 12.

6.

CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.

Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T.

Drug Metab Pharmacokinet. 2004 Apr;19(2):120-9.

7.

Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.

Walsky RL, Obach RS, Hyland R, Kang P, Zhou S, West M, Geoghegan KF, Helal CJ, Walker GS, Goosen TC, Zientek MA.

Drug Metab Dispos. 2012 Sep;40(9):1686-97. doi: 10.1124/dmd.112.045302. Epub 2012 May 29.

8.

Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.

Wang YH, Jones DR, Hall SD.

Drug Metab Dispos. 2005 May;33(5):664-71. Epub 2005 Feb 2.

9.

Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.

Hardy KD, Wahlin MD, Papageorgiou I, Unadkat JD, Rettie AE, Nelson SD.

Drug Metab Dispos. 2014 Jan;42(1):162-71. doi: 10.1124/dmd.113.054817. Epub 2013 Nov 4.

10.
11.

Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.

McConn DJ 2nd, Lin YS, Allen K, Kunze KL, Thummel KE.

Drug Metab Dispos. 2004 Oct;32(10):1083-91.

12.

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA.

Drug Metab Dispos. 2002 Aug;30(8):883-91.

13.

Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).

He K, Woolf TF, Hollenberg PF.

J Pharmacol Exp Ther. 1999 Feb;288(2):791-7.

15.

Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone.

Hong Y, Chia YM, Yeo RH, Venkatesan G, Koh SK, Chai CL, Zhou L, Kojodjojo P, Chan EC.

Mol Pharmacol. 2016 Jan;89(1):1-13. doi: 10.1124/mol.115.100891. Epub 2015 Oct 21.

PMID:
26490246
16.

Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites.

Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD.

Xenobiotica. 2002 Oct;32(10):863-78.

PMID:
12419016
17.

Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5.

Okada Y, Murayama N, Yanagida C, Shimizu M, Guengerich FP, Yamazaki H.

Drug Metab Dispos. 2009 Jan;37(1):18-23. doi: 10.1124/dmd.108.024679. Epub 2008 Oct 23.

18.
19.

Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic alpha,beta-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme.

Kassahun K, Skordos K, McIntosh I, Slaughter D, Doss GA, Baillie TA, Yost GS.

Chem Res Toxicol. 2005 Sep;18(9):1427-37.

PMID:
16167835
20.

Comparison of cytochrome P450 3A enzymes in cynomolgus monkeys and humans.

Iwasaki K, Murayama N, Koizumi R, Uno Y, Yamazaki H.

Drug Metab Pharmacokinet. 2010;25(4):388-91.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk